Robert Lutjens has been promoted to the executive management team of Addex Therapeutics Ltd to lead scientific development of the company’s small molecule allosteric modulators for neurological disorders. He joined the company in 2002 and is head of drug discovery. In addition, Roger Mills, the chief medical officer and a board member, will take on a broader role in leading the transition of preclinical compounds into first-in-man studies. Addex’s lead programme is poised to start pivotal studies in levodopa-induced dyskinesia associated with Parkinson’s disease.
Addex announced the management changes on 18 September 2017.
Copyright 2017 Evernow Publishing Ltd